40. Panchalingam KM, Jung S, Rosenberg L,

Behie LA (2015) Bioprocessing strategies for

the large-scale production of human mesen-

chymal stem cells: a review. Stem Cell Res

Ther

6:225.

https://doi.org/10.1186/

s13287-015-0228-5

41. Spees JL, Gregory CA, Singh H et al (2004)

Internalized antigens must be removed to pre-

pare hypoimmunogenic mesenchymal stem

cells for cell and gene therapy. Mol Ther

9:747–756.

https://doi.org/10.1016/j.

ymthe.2004.02.012

42. Zheng X, Baker H, Hancock WS et al (2006)

Proteomic analysis for the assessment of differ-

ent lots of fetal bovine serum as a raw material

for cell culture. Part IV. Application of proteo-

mics to the manufacture of biological drugs.

Biotechnol Prog 22:1294–1300. https://doi.

org/10.1021/bp060121o

43. Kuri-Harcuch W, Green H (1978) Adipose

conversion of 3T3 cells depends on a serum

factor. Proc Natl Acad Sci 75:6107–6109.

https://doi.org/10.1073/pnas.75.12.6107

44. European Medicines Agency (2013) Use of

bovine serum in the manufacture of human

biological medicinal products. In: European

Medicines Agency. https://www.ema.europa.

eu/en/use-bovine-serum-manufacture-

human-biological-medicinal-products.

Accessed 30 May 2021

45. Nikolits I, Nebel S, Egger D et al (2021)

Towards physiologic culture approaches to

improve standard cultivation of mesenchymal

stem cells. Cells 10:886. https://doi.org/10.

3390/cells10040886

46. Muoio F, Panella S, Jossen V et al (2021)

Human adipose stem cells (hASCs) grown on

biodegradable microcarriers in serum- and

xeno-free

medium

preserve

their

undifferentiated

status.

J

Funct

Biomater

12:25.

https://doi.org/10.3390/

jfb12020025

47. Kaiser S, Jossen V, Schirmaier C et al (2013)

Fluid flow and cell proliferation of mesenchy-

mal adipose-derived stem cells in small-scale,

stirred, single-use bioreactors. Chem Ing Tech

85:95–102.

https://doi.org/10.1002/cite.

201200180

48. dos

Santos

F,

Campbell

A,

Fernandes-

Platzgummer A et al (2014) A xenogeneic-

free bioreactor system for the clinical-scale

expansion of human mesenchymal stem/stro-

mal cells: xeno-free production of human

MSC. Biotechnol Bioeng 111:1116–1127.

https://doi.org/10.1002/bit.25187

49. Cunha B, Aguiar T, Carvalho SB et al (2017)

Bioprocess integration for human mesenchy-

mal stem cells: from up to downstream proces-

sing scale-up to cell proteome characterization.

J Biotechnol 248:87–98. https://doi.org/10.

1016/j.jbiotec.2017.01.014

50. Panella S, Muoio F, Jossen V et al (2021)

Chemically defined xeno- and serum-free cell

culture medium to grow human adipose stem

cells. Cells 10:466. https://doi.org/10.3390/

cells10020466

51. Jossen V, Muoio F, Panella S et al (2020) An

approach towards a GMP compliant in-vitro

expansion of human adipose stem cells for

autologous therapies. Bioengineering 7:77.

https://doi.org/10.3390/

bioengineering7030077

52. Jossen V, van den Bos C, Eibl R, Eibl D (2018)

Manufacturing human mesenchymal stem cells

at clinical scale: process and regulatory chal-

lenges.

Appl

Microbiol

Biotechnol

102:3981–3994.

https://doi.org/10.1007/

s00253-018-8912-x

Mesenchymal Stem Cell Expansion at Benchtop-Scale

111